Publication | Open Access

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

VaccinationVaccine SafetyVaccinologyVaccine DevelopmentImmunologyImmunodominanceInterim ResultsVaccine EfficacyImmunotherapeuticsDose-ranging StudyMedicinePhase 1–2Covid-19